OCTH.F Stock Overview
A pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Oxford Cannabinoid Technologies Holdings Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0028 |
| 52 Week High | UK£0.044 |
| 52 Week Low | UK£0.0028 |
| Beta | 0.82 |
| 1 Month Change | -45.10% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| OCTH.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | 1.7% |
| 1Y | n/a | 15.0% | 26.3% |
Return vs Industry: Insufficient data to determine how OCTH.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how OCTH.F performed against the US Market.
Price Volatility
| OCTH.F volatility | |
|---|---|
| OCTH.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: OCTH.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine OCTH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 7 | Clarissa Sowemimo-Coker | www.oxcantech.com |
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate consists of OCT461201, an CB2 receptor, that is in phase – I clinical trial for use in the treatment of chemotherapy-induced peripheral neuropathy and irritable bowel syndrome (IBS), as well as in neuropathic and visceral pain conditions. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia.
Oxford Cannabinoid Technologies Holdings Plc Fundamentals Summary
| OCTH.F fundamental statistics | |
|---|---|
| Market cap | US$2.14m |
| Earnings (TTM) | -US$5.39m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs OCTH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCTH.F income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£2.33m |
| Gross Profit | -UK£2.33m |
| Other Expenses | UK£1.91m |
| Earnings | -UK£4.24m |
Last Reported Earnings
Oct 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0039 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did OCTH.F perform over the long term?
See historical performance and comparison